In Japan, several thousand people, three-quarters of whom were war-wounded, have been administered Thorotrast. An epidemiological follow-up study on Thorotrast-administered war-wounded veterans was initiated in 1963. The 7th survey of the study was conducted on 286 veterans at the end of 1986, of whom 262 had received Thorotrast intravascularly and 24 by other routes.
INTRODUCTION
In 1963, an epidemiological follow-up study was started on 147 veterans who had received Thorotrast in the diagnosis of their war-wounds. 1) By the end of 1986, the study had been extended owing to newly found cases up to 286 subjects. On 31 December 1986, the 7th survey in the follow-up study (hereafter referred to as the Japanese study) was made on those 286 veterans, 262 of whom had received Thorotrast intravascularly and 24 of whom had been given the compound by other routes.2) We here present findings obtained in the further analyses of persons who had received Thorotrast intravascularly.
Data from 94 autopsies of persons administered Thorotrast intravascularly, were col lected from medical schools and hospitals until 1973.3) These data were used in the first series of Thorotrast-administered autopsy patients. The series has expanded gradually and by 1990 included 357 autopsy cases2) (Note 1). Results of the statistical analyses of the data for Thorotrast-administered autopsy materials and control autopsy materials are also described in this paper.
Of the materials obtained from these autopsies, a dosimetric study of the Thorotrast patients was made. The dosimetric results for the liver, spleen and bone marrow are likewise also reported here.4)
MATERIALS AND METHODS
Follow-Up Study of Patients Administered Thorotrast Intravascularly.
In the study of intravascular Thorotrast administrated patients, we are following 262 veterans who had been given Thorotrast intravascularly for the diagnosis of their war injuries. The average amount of Thorotrast injected per person was 17 ml (SD 17 ml). We also have examined a control group of 1,630 war-wounded veterans who had no record of Thorotrast administration. The members of the control group were selected from those who had been treated at the same time in the same hospitals.
The time of Thorotrast injection or war-injury ranged from 1937 to 1945. The ages at injection of the subjects in the Thorotrast group (hereafter, the Thorotrast group) and the ages of the war-wounded in the control group ranged from 20 to 39 years old, the mean age at injection being 25.8 years (SD 4.1 years) for the Thorotrast group and the wounding for the control group being 24.8 years (SD 4.4 years).
The subjects in both groups were divided by ages into four 5-year-subgroups. The distribution of the control subjects was equivalent to that of the Thorotrast ones in each 5-year-subgroup. 2, 5, 6) In the 7th survey that made on 31 December 1986 (41-49 years after Thorotrast injection), 58 persons were alive, 197 had died and 7 were untraceable in the Thorotrast group. Of the control group, 886 were alive and 744 had died. The distribution of ages of the persons in the Thorotrast group at the time of injection and in the control group at the time of war injury are shown in Table 1 , in which the number of Thorotrast patients is 255 not 262 because 7 persons were untraceable.
Results of the first analysis of the data obtained in the survey were presented at the workshop "Risks from Radium and Thorotrast" held at Bethesda, Maryland, USA and were complied in the BIR Report 21.2)
We herewith present some new findings which were found after further analyses of the data acquired in the survey. In the previous papars2'5), we reported that Thorotrast carriers showed a constant tendency to die earlier than the controls. This phenomen was also (Note 1) 2) This series includes data on a few biopsy materials taken from critical organs for terminal diagnosis . recognized in a German Thorotrast study? (hereafter, the German study). In addition, this study of Germany showed that the lifespans of the Thorotrast carriers decreased markedly when there was an increase in the amount of Thorotrast injected. Using the same procedure as in the German study, we grouped our subjects into 3 cohorts on the basis of the amount of Thorotrast injected; (a) 1-10 ml (n=125), (b) 11-20 ml (n=97), and (c) >20 ml (n=33) plus the controls (n=1,630). Results of our analysis using the Kaplan-Meier method on these distributed data reviewed almost the same patterns as in the German study? (Fig. 1) . The difference between the final fates of the Thorotrast carriers and controls is the most important parameter in the estimation of the late effects of Thorotrast administration. 8,9) Therefore, we classified the diseases found in the Thorotrast subjects and the controls into seven categories 2) ; (I) so-called Thorotrast-related diseases, (II) secondary disorders induced by the diseases present at the time of Thorotrast admin istration, (III) so-called non-Thorotrast-related malignant tumors, (IV) infectious disease, (V) non-infectious disease, (VI) accidents and injuries, and (VII) unknown.
A comparison of the cause-specific mortality rates showed that deaths due to malignant liver tumors, cirrhosis of the liver, blood diseases, epilepsy and cancer of the extrahepatic bile duct were significantly higher in the Thorotrast group than in the controls. 2) These diseases are shown in Tables 2 and 3 , with the values of the significance level (by the chi-square test) and the ratios of the observed to expected incidence in the Thorotrast group. Of these diseases, epilepsy was concluded to be a result of the head trauma, a main reason for Thorotrast injection in Japanese veterans. Hence, it was classified in category II; secondary disorders induced by the diseases present at the time of Thorotrast administration2)
. Malignant liver tumors, cirrhosis of the liver and blood diseases already had been recognized as Thorotrast-specific diseases by many researchers. 8'9.10) Therefore, we classified them into category I; so-called Thorotrast-related diseases. Of these diseases, the highest rate is for the incidence of malignant liver tumors. The ratio of the observed to the expected incidence of the liver tumors in the Thorotrast group has been aca. 30 over the past 20 years in our study 2,5) which is about one-fifth of that (155) found in the German study .7 The most plausible explanation for this difference is the disparity in the incidences of natural hepatic malignancies in Germany and Japan; natural malignant hepatic tumors caused only 0.11% of the total deaths in the control group in the German study, but 0.67% of the total deaths in the control group in the Japanese study 2'7 Thus, the ratio (1:6) of the incidences of malignant hepatic tumors in the controls (the natural incidences of the malignant hepatic tumors) in the German and Japanese studies could explain most of the causes of disparity in both studies. The high incidence of hepatic malignancies in the controls in the Japanese study might be due to the comparatively high incidence of liver cell carcinomas in the population of Japan. It is well known that the incidence of liver cell carcinomas is markedly higher in the Japanese population than in the populations of European countries. 4) In addition, we use the Kaplan-Meier method to determine whether the diseases, other than those in categories I and II, have any effect on the dose-rate-dependent lifespan shortening of the Thorotrast carriers. Results show dose-rate-dependent lifespan shortening, similar to that seen in Fig. 1 , also occurr with diseases other than those in categories I and II (Fig. 2) . This kind of dose-rate-dependent shortening of the lifespan was already found in the German study. 7 Consequently, these paralleled findings in both studies suggest the possibility that some diseases belonging to categories III to VII may be related to the late effects of Thorotrast administration.
Risks of the so-called non-Thorotrast-related malignant tumors (category III) are shown in Table 3 . Of those tumors, cancer of the extrahepatic bile duct shows a significantly higher rate in the Thorotrast carriers than those in the controls. The excess of this cancer in the Thorotrast carriers was also found in the German study.') These identical findings in both studies suggest that, in the carriers, the late effects of Thorotrast administration should increase this cancer's incidence. The causes of death in the Thorotrast and control autopsy series showed some biases in regard to the ratios of malignant tumors to other diseases: In these two series, the ratios of death from malignancies were 2 and 1.8 times higher, whereas the ratios of death from other diseases were 0.6 and 0.25 times lower when compared to those in the Thorotrast group and the controls in the follow-up study, respectively.
The reason for these biases in the ratios of malignancies to other diseases is follows; in Japan, the pathological autopsies have a tendency to be made more frequently on the cases who died of malignant tumors than on the cases who died from other diseases. This tendency was also seen in the deaths of Japanese Thorotrast patients. 2) In all, 357 intravascular Thorotrast patients were autopsied between 1945 and 1990 (Table 4) . In this survey, the subjects constitute the "Thorotrast autopsy series (hereafter, the Thorotrast series)." The male to female ratio was 8.9:1. These cases had received Thorotrast between 1928 and 1954, the age at the time of injection ranging from 9 to 47 years (mean; 25 years). The age at death was from 35 to 85 years, and the period between Thorotrast administration and death ranged from 11 to 53 years (mean; 32 years). The 160,700 control subjects of the same age range (35-89 years) were selected from the non-Thorotrast-administered autopsy cases which recorded in the Pathological Autopsy Cases in Japan for the 1958-1986 period,") by a manner previously reported (hereafter, the control series).6,12) The ratios of the numbers of cases in the 5-year-age-classes and the male to female ratio in the control series were adjusted to the ratios found in the Thorotrast series (Note 2).
A comparison of the incidences of deaths from diseases in category I (so-called Thorotrast-related diseases) for the Thorotrast and control series is shown in Table 4 . The frequencies of malignant liver tumors were 67.2% in the Thorotrast series and 8.0% in the control series, which are higher when compared with those in our follow-up study (malignant liver tumors caused 22.0% of all deaths in the Thorotrast group and 0.7% in their controls). This difference suggests that patients with known or suspected liver malignancies were more likely to be given autopsies in medical schools and hospitals (Note 2).
The frequency of malignant liver tumors was found to be significantly higher in the Thorotrast series than in the control series by the chi-square test (p<0.001). The ratio of the number of malignant liver tumors observed to that expected was 8.4 in the Thorotrast series (Table 4) . A study of these autopsy series indicated that a remarkable chronological change occured in the proportions of histological types of malignant liver tumors in the Thorotrast series during the past 45 years since 1945 (Table 5 ). The proportion of liver cell carcinomas increased from 13.1% for 1945-1975 to 17.3% for [1976] [1977] [1978] [1979] [1980] [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] [1990] . Similarly, the proportion of hemangiosarcomas increased from 20.6% for 1945-1975 to 24.8% for [1976] [1977] [1978] [1979] [1980] [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] [1990] . In contrast, the proportion of cholangiocarcinomas decreased from 57.0% for 1945-1975 to 35.3% for [1976] [1977] [1978] [1979] [1980] [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] [1990] . However, the most extraordinary change was found in the incidence of combined malignant tumors (Note 3).
The proportion of combined malignant tumors increased from 6.5% for 1945-1975 to 22.6% for 1976-1990 because of the increase in double to tetradic malignacies in the same liver or in the liver and other organs (Tables 5 and 6 ). A third of the combined malignacies in the Thorotrast series included hepatic hemangiosarcoma or liver cancer (liver cell cancer, cholangiocarcinoma, etc.) as elemental tumors.13.14) The proportion of combined malignant liver tumors, (double to tetradic malignant tumors in the same liver) was 2.7 times higher in the 1976-1990 period than in the 1945-1975 period in the Thorotrast carriers. Moreover, the proportion of combined malignant liver tumors in the 1976-1990 period was 10.9 times higher in the Thorotrast carriers than in the histological controls (Note 4). This observation suggests that the histological types of liver malignancies in Thorotrast carriers become more complex as time goes on.
As shown in Table 6 , different histological types of hepatic malignancies in the same liver are rare in Japan, and the possibility of hepatic hemangiosarcoma occurring with liver cancer in a liver is even more rarely, we, however, found 6 cases of combined hepatic malignancy consisted of hemangiosarcoma and liver cancer in our Thorotrast series. 12,13,14) Wegener15) also found 2 cases of the same kind of tumor in the German study. 15) These findings suggest that alpha-ray irradiation from Thorotrast granules deposited in the liver induces this kind of hepatic malignancy in the human being.
Of the other diseases in category I (Table 4) , the incidence of cirrhosis of the liver was 6.4% in the Thorotrast series and 9.7% in the control series, no significant difference existed between the two series. There were 28 cases of blood diseases (19 leukemias and 9 other diseases) in the Thorotrast series. The incidence of the blood diseases (7.8%) in the Thorotrast series was not significantly different from that (7.7%) in the control series. In addition, one bone sarcoma, two hemangiosarcomas of the spleen, five tumors at the injection site (three sarcomas and two necrotic thorotrastomas) and 11 lung cancers were found in the Thorotrast series. Risks of malignant tumors belonging to category III (so-called non-Thorotrast-related malignant tumors) are shown in Table 7 . Of these malignancies, malignant peritoneal tumors (4 cases) were significantly higher in the Thorotrast series than in the controls (p<0.001).
The four malignant peritoneal tumors (one malignant mesothelioma and three sarcomas) in our Thorotrast series is of interest in relation to the findings in the German study. 7,8) Kaick, et al .7 found 3 pleural and 2 peritoneal malignant mesotheliomas in 2,326 intra vascular Thorotrast cases, they examined, but no mesotheliomas were found in the 1,890 controls. They speculated that this kind of tumor might be induced by alpha-ray irradiation from Thorotrast granules deposited in the human body. The data from our Thorotrast study support this idea, since two pleural malignant mesotheliomas were found in persons who had been given Thorotrast intrapeurally2), added to the above-mentioned peritoneal tumors. To avoid error in the measuring of dose rates in the bone marrow samples, we used only materials taken from the body within one year after death. Consequently, the specimens examined were limited to the materials got from 27 autopsy subjects.4)
DOSE ESTIMATION
The dose rates and doses from the time of Thorotrast injected to death in the liver, spleen and bone marrow were estimated from materials obtained in the Thorotrast autopsy series, using the method which we described previously. 16, 17) Estimation of the dose rates were made from specimens of liver obtained from 147 subjects, spleen from 128 subjects and bone marrow from 27 subjects ( Table 8 ) (Note 5).
The mean dose rate was 26.1 cGy/year in the liver, 91.2 cGy/year in the spleen and 8.5 cGy/year in bone marrow. 4,18) The mean dose from the time of Thorotrast injection until death was 837 cGy in the liver and 2,020 cGy in the spleen.
CONCLUSION
In an extended study of the phenomena found in the 7th survey of the follow-up study of 255 patients who had been given Thorotrast intravascularly, we analyzed the amount of Thorotrast injected in relation to cause of patient deaths. When compared with those of the 1,630 controls, the lifespans of the Thorotrast patients were shortened dose-rate-dependently.
This dose-rate-dependent life-shortening was found not only in the patients who died from the so-called Thorotrast specific diseases, but also in the patients who died from the so-called non-Thorotrast-related malignant tumors. These findings provide proof of the relation between intravascular Thorotrast administration and the diseases such as carcinoma of the extrahepatic bile duct and peritoneal malignant tumors which were statistically proved to have higher incidences in Thorotrast cases than in the controls.
A total of 357 intravascular Thorotrast cases were autopsied from 1945 to 1990. Statistical analyses revealed a chronological change occurring in the proportion of histological types of hepatic malignancies in the Thorotrast carriers in the 45 years since 1945. The most remarkable change in this period was in the incidence of combined malignant liver tumors; their proportion among hepatic malignancies in the 1976-1990 period being 3.5 times higher than that in the 1945-1975 period. Other findings show concern with the chronological change in the histological patterns of hepatic malignancies. 6,12) This observation suggests that histological types of liver malignancies in the Thorotrast carriers become more complex with time. This complexity may be induced by long-term alpha-ray irradiation from Thorotrast granules deposited in the liver. 
